title: Outcome in carcinoma in situ of bladder treated with intravesical bacille Calmette-Guérin.
abstract: Fifty-three patients with carcinoma in situ of the bladder were treated with Evans strain BCG given intravesically. Complete remission was achieved after either one or two 6-weekly courses in 53% of patients. The median duration of remission was 32 months. Treatment-related bladder symptoms were minor during the first course, more severe during the second. There was no relation between severity of symptoms and likelihood of response. With a median follow-up of 32 months, disease progression has occurred in 10% of complete responders, whereas failure to respond on either cystoscopic, histological or cytological grounds was associated with a 48% progression rate. Although intravesical BCG produces impressive responses in carcinoma in situ of the bladder, managed conservatively the condition remains a dangerous one.
authors.affiliation: St Peter's Hospital, London.
authors.forename: S J
authors.initials: SJ
authors.lastname: Harland
authors.forename: C R
authors.initials: CR
authors.lastname: Charig
authors.forename: W
authors.initials: W
authors.lastname: Highman
authors.forename: M C
authors.initials: MC
authors.lastname: Parkinson
authors.forename: P R
authors.initials: PR
authors.lastname: Riddle
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000473:pathology / Q000652:urine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000652:urine
chemical_list: D001500:BCG Vaccine